Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

Abstrakt

Tyrosine kinase inhibitors have completely changed the prognosis of patients with Ph+ chronic myeloid leukemia (CML). The occurrence of a second malignancy in CML patients successfully treated with tyrosine kinase inhibitors may significantly affect their prognosis.

Klíčová slova

• chronic myeloid leukemia
• tyrosine kinase inhibitor
• incidence
• second malignancy